Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03529786 · ClinicalTrials.gov registry record
Mucopolysaccharidosis Type II Natural History
A clinical trial, sponsored by REGENXBIO.
- Completed
- Registry status
- 36
- Enrollment target
NCT03529786 is a clinical trial that has completed, run by REGENXBIO. The registered enrollment target is 36 participants.
The verdict
NCT03529786 has completed, sponsored by REGENXBIO.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is caused by a deficiency of iduronate-2-sulfatase (IDS) leading to an accumulation of glycosaminoglycans (GAGs) in tissues of MPS II patients, resulting in characteristic storage lesions and diverse disease sequelae, and in patients with the more severe form of the disease, irreversible neurocognitive decline and higher morbidity and mortality than in patients with the attenuated form of the disease. There is currently limited information on the natural history of MPS II, especially with respect to neurocognitive decline in patients with the more severe form of the disease. This study is planned to be an observational medical records review study (data collected retrospectively and no investigational product treatment or procedures) in subjects with the severe form of MPS II. Collectively, the data may inform the design of future MPS II gene therapy treatment studies and may be utilized as historical comparative control data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2022-03-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03529786
The ClinicalTrials.gov registry entry for NCT03529786 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is REGENXBIO, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03529786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03529786 about?
NCT03529786 is a clinical study titled "Mucopolysaccharidosis Type II Natural History". Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is caused by a deficiency of iduronate-2-sulfatase (IDS) leading to an accumulation of glycosaminoglycans (GAGs) in tissues of MPS II patients, resulting in characteristic storage lesions and diverse disease sequelae, and in pati...
What is the current status of trial NCT03529786?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2017-09-27. Estimated completion is 2022-03-22.
Who is sponsoring clinical trial NCT03529786?
This trial is sponsored by REGENXBIO, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.